aTYR PHARMA INC
Company Stats
- Market Cap
- $29.7M
- as of Sep 30, 2026
- Shares Outstanding
- 98.1M
- Free Float
- 91.1%
Income Statement
- Revenue
- $190,000
- Operating Income
- -$77.6M
- Net Income
- -$74.1M
- EBITDA
- -$77.0M
- Revenue Growth, 3Y
- -73.7%
- FCF Margin, 3Y Avg
- -24236.6%
- FCF Margin, Worst Year
- -32664.7%
Cash Flow
- Free Cash Flow
- -$62.1M
- FCF Yield
- -208.8%
- Owner FCF Yield
- -225.6%
Balance Sheet
- Cash & Equivalents
- $10.7M
Returns & Capital
- SBC, 3Y Avg
- $3.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $190,000 | -$62.1M | -32664.7% |
| FY2024 | $235,000 | -$69.2M | -29440.0% |
| FY2023 | $353,000 | -$37.4M | -10605.1% |
| FY2022 | $10.4M | -$43.5M | -419.1% |
| FY2021 | $0 | -$33.3M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges